Compare Synopsys, Inc. (SNPS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Tango Therapeutics Inc. — how do they compare? Synopsys, Inc. trades at $477.99 (market cap $94.77B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Synopsys, Inc. is far larger — about 25.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 2,520,237). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 72 Days and Tango Therapeutics Inc. for 0 Days on average.
| SNPS | TNGX | |
|---|---|---|
Market Cap | $94.77B | $3.75B |
Volume | 2,520,237 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $534.56 | $32.90 |
52-Week Low | $367.70 | $7.50 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $102.00B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $479.93, down 4.49% today but remains in a strong technical uptrend with bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5% and maintains strong profitability with 72.38% gross margins. Recent investor day announcements highlighted transformative AI partnerships with OpenAI and Amazon, driving positive sentiment and analyst upgrades.
Outlook remains positive with 93% analyst buy ratings and $575.93 consensus target offering 20% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks involve execution challenges and premium valuation at 86.3 P/E. The stock presents a compelling growth story but requires monitoring of integration progress and competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
